

Kerbel R. S., (2008). Tumor angiogenesis. *New England Journal of Medicine*, 358(19), 2039-2049.

Kerbel, R. S. (2000). Tumor angiogenesis: past, present and the near future. *Carcinogenesis*, 21(3), 505-515.

Kerbel, R., & Folkman, J. (2002). Clinical translation of angiogenesis inhibitors. *Nature Reviews Cancer*, 2(10), 727-739.

Kim, Y. M., Hwang, S., Kim, Y. M., Pyun, B. J., Kim, T. Y., Lee, S. T., ... & Kwon, Y. G. (2002). Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. *Journal of biological chemistry*, 277(31), 27872-27879.

Kim, Y. M., Jang, J. W., Lee, O. H., Yeon, J., Choi, E. Y., Kim, K. W., ... & Kwon, Y. G. (2000). Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase 2. *Cancer research*, 60(19), 5410-5413.

Krause, D. S., & Van Etten, R. A. (2005). Tyrosine kinases as targets for cancer therapy. *New England Journal of Medicine*, 353(2), 172-187.

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., ... & Haber, D. A. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. *New England Journal of Medicine*, 350(21), 2129-2139.

Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000). Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. *Journal of Controlled Release*, 65(1), 271-284.